secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001599298-25-000044
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics reports FY2024 net loss $221.3M; HARMONi enrollment complete, data mid-2025
--------------------------------------------------------------------------------

- Cash & short-term investments $412.3M at Dec 31, 2024, up from $186.2M at Dec 31, 2023.
- GAAP net loss $221.3M ($0.31/share) vs $614.9M ($0.99/share) prior year.
- GAAP R&D expense $150.8M vs $59.4M prior year, driven by ivonescimab development.
- HARMONi Phase III trial enrollment complete; top-line data expected mid-2025; FDA Fast Track granted.
- Pfizer collaboration to evaluate ivonescimab with vedotin ADCs in solid tumors; studies start mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000044/0001599298-25-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000044/smmt-20250224.htm
  HTML page:      https://secwatch.observer/filing/0001599298-25-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer